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CLINICAL ANALYSIS OF BLADDER CANCER PATIENTS 
UNDERGOING RADICAL CYSTECTOMY 
Yasuto KATO， Yoshihiro HASEGAWA， Toshiaki WAKITA and Norio HAYASHI 
The Department of Urology， Aichi Cancer Center 
A retrospective clinicopathological study was performed on 96 bladder cancer patients who 
underwent radical cystectomy and pelvic lymphadenectomy at Aichi Cancer Center between April1994 
andJuly 2004. The followべlpperiod ranged from 4 to 109 months， with a mean of 39.1 months. The 
overall cancer-specific survival rates at 3， 5 and 7 years were 81. 7 %， 71.2 % and 71.2 %， respectively. 
The 5-year survival rate according to pathological stage was 97.3 %あrpTl or lower， 66.4% for pT2， 
47.6 % for pT3， and 25.4 % for pT4. U nivariate analysis demonstrated the prognostic significance of 
pathological stage (p<O.OOI)， lymph node metastasis (p=O.OOl)， venous invasion (p<O.OOl)， 
Iymphatic invasion (p=0.010)， preoperative creatini町 clearance (p=O.OOl) and preoperative 
hydronephrosis (p<O.OOl). Multivariate analysis revealed strong independent correlations ofvenous 
invasion (p=0.040) and preoperative hydronephrosis (p=0.016) with prognosis. 
(Hinyokika Kiyo 51: 719-725，2005) 

















































trexate， vincristin， doxorubicin and cisplatin) 1 ~ 2 
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Characteristic 




Follow up period (months) 
Male 
Female 
29-82 (mean 64.9) 
4-109 (mean 39.1) 





Pathological T classification pTI or lower 
pT2 
pT4 





Additional therapy Neoadjuvant 
MVAC 
NEC 
Adjuvant (MV AC) 
Ileal cond ui t 
Ileal neobladder 














9 ( 9.4) 
84 (87目5)
12 (12.5) 







コースであり， 1例のみ MEC療法 (methotrexate，



















全症例における疾患特異的生存率は 3年81.7%， 5 
年および7年生存率71.2%と良好であった (Fig.1). 
Clinical stage別5年生存率は grade3の上皮肉癌およ
び cTlgrade 3 100%， cT2 74.5%， cT3 48.8%， cT4 
68.2%であり (Fig.2)， pathological stage別5年生存
71.2% 
o 10 5 
Years after cystectomy 
Fig. 1. Cause-specific survival rate in al 96 patients. 
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cT3 ' 48.8% (n=11) 
o 
o 5 
Years after cystectomy 
10 
Fig. 2. Survival rate according to clinical stage 
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o 5 10 
Years after cystectomy 
Fig. 3. Survival rate according to pathological stage. 
100 町~ー P < 0.001 
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Hydronephrosis(+): 33.4% (n=18) 
o 5 10 
Years a積ercystectomy 
Fig. 4. Survival rate according to hydronephrosis， 
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100 P = 0.001 













o 10 5 
Years after cystectomy 
Fig. 5. Survival rate according to lymph node metastasis 
100 i &:.ー 'ー"'L- P < 0.001 














V(う I 78.5% (n=40) 
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o 10 5 
Years after cystectomy 
Fig. 6. Survival rate according to venous invasion 
率は pT1以下97.3%，pT2 66.4%， pT3 47.6%， 















Table 2. Multivariate analysis of prognostic factors in patients undergoing radical cystectomy 
Variablc Catcgories Hazard ratio (95 % CI) P-value 
Pathological stage pT2 or less/pT3 or more 0.807 (0.154-4.239) 0.800 
Lymph node mctastasis posi tive/ncgativc 。目391(0.066-2.311) 0.301 
Venous invasion positive/negative 0.139 (0.02ト0.911) 0.040 
Lymphatic invasion positive/ne耳ative 。目488(0.143-1.667) 0.252 
Hydronephrosis positive/negative 0.190 (0.049-0.733) 0.016 
Creatinine clearance 孟60m1/min <60 m1/min 。目428(0.093-1.967) 0.275 
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5 ( 6.8%) 
4 ( 5.5%) 






1 ( 5.6%) 
o (0 %) 
3 (16.7%) 































o 10 5 
Years after cystectomy 
Fig. 7. Survival rate according to adjuvant therapy in patients with venous invasion. 

































いこと (Table4)， grade 3の移行上皮癌および非移行
上皮癌(肩平上皮癌と小細胞癌が各2例，腺癌が l
例)の割合が71.0%と多いことによると考えられた.
また， pTI以下の症例が37例 (38.5%) と多い傾
向にあったことに関して，その内訳は pTO5例， pTis 
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Table 4. Relationship between pathological T classification and Iymph node metastasis 
Parhological T classification Number (%) Number or pN (+) (%) 
pTO 5 (13.5) 0(0) 
pTis 5 (13.5) 0(0) 
pTa 7 (18.9) 0(0) 
pTl 20 (54.1) 0(0) 
pT2a 1 (35.5) 0(0) 
pT2b 20 (64.5) 6 (33.3) 
pT3a 6 (31.6) 1 (5.6) 
pT3b 13 (68.4) 6 (33.3) 
pT4a 6 (66.7) 3 (16.7) 
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